GLP-1 telehealth marketing sits at the intersection of FDA drug advertising rules, FTC weight loss claim restrictions, and state compounding regulations.
The FDA sent “thousands” of warning letters to telehealth and pharmaceutical companies in September 2025, with GLP-1 marketing as a primary focus. This isn’t theoretical risk. It’s active enforcement.
To market GLP-1 services compliantly: distinguish between FDA-approved branded medications and compounded versions, substantiate all efficacy claims with clinical evidence, and never promise specific weight loss outcomes.
The GLP-1 regulatory landscape right now
FDA-approved options:
- Wegovy (semaglutide) — approved for chronic weight management
- Zepbound (tirzepatide) — approved for chronic weight management
- Ozempic (semaglutide) — approved for type 2 diabetes, used off-label for weight loss
Compounded options:
- 503A compounding — patient-specific prescriptions
- 503B compounding — bulk manufacturing for office use
Active enforcement:
- September 2025: FDA/FTC sent “thousands” of warning letters
- Primary focus: GLP-1 claims, compounding marketing, weight loss promises
- Ongoing litigation: OFA v. FDA on compounding restrictions
What you can say about FDA-approved GLP-1s
For FDA-approved medications, you can reference the approved labeling:
Permitted:
- “FDA-approved for chronic weight management”
- “In clinical trials, patients lost an average of X% body weight”
- “Contains semaglutide” or “Contains tirzepatide”
- “Prescribed by licensed physicians after medical evaluation”
Not permitted:
- “Lose 30 pounds” — specific outcome promises
- “Guaranteed weight loss” — no guarantee exists
- “Cures obesity” — not in approved labeling
- “Better than [competitor]” — requires head-to-head data you probably don’t have
What you can say about compounded GLP-1s
For compounded medications, you have less room:
Permitted:
- Ingredient and dosing information
- “Compounded by a licensed 503A/503B pharmacy”
- “Contains semaglutide, the same active ingredient as Wegovy”
- Pricing information
Not permitted:
- “FDA-approved” — compounded drugs are not FDA-approved
- “Same as Wegovy” or “Equivalent to Wegovy” — implies interchangeability
- Efficacy claims without your own clinical data
- “Bioidentical” without substantiation
The phrase “same active ingredient” is permitted. The phrase “same as” is not. The distinction matters.
Claims that will trigger enforcement
Based on recent FTC and FDA enforcement patterns, avoid:
Specific outcome promises: “Lose 30 pounds in 30 days” is unsubstantiated and will draw scrutiny.
Guaranteed results: “Guaranteed weight loss” doesn’t exist in medicine. Saying it is false advertising.
Before/after without context: Patient transformation photos require proper disclosures about typical results. Exceptional outcomes must be clearly labeled as exceptional.
Testimonials without disclaimers: Patient testimonials require HIPAA authorization and FTC-compliant disclosures about what results are typical.
FDA approval claims for compounded drugs: Compounded medications are not FDA-approved. Saying or implying otherwise is a violation.
The compounding gray zone
Compounding is permitted when FDA-approved drugs are in shortage. This creates marketing complexity:
While in shortage:
- You can market compounded versions
- You cannot make the same efficacy claims as the branded version
- You must substantiate any efficacy claims independently
When shortage ends:
- Compounding restrictions tighten
- Marketing claims may need to change
- Monitor FDA shortage list
The shortage status changes. Your marketing must be able to adapt.
Platform-specific restrictions
Google Ads:
- LegitScript certification required for prescription telehealth advertising
- Healthcare and medicines policy applies
- Personalized advertising restrictions for health conditions
Meta (Facebook/Instagram):
- Weight loss is a Special Ad Category
- Restricted targeting based on health conditions
- Claim scrutiny is high
TikTok:
- Pharmaceutical promotion largely prohibited in US
- Very limited telehealth options
LinkedIn:
- B2B positioning may have fewer restrictions
- Still subject to FTC substantiation requirements
Building a compliant GLP-1 marketing strategy
Lead with the service, not the drug. “Physician-supervised weight management” is safer than “Get semaglutide.”
Emphasize the medical evaluation. “Consultation with a licensed physician to determine if this treatment is right for you” positions appropriately.
Reference clinical data correctly. Cite FDA-approved labeling data, not cherry-picked studies.
Prepare for shortage changes. Build marketing that works whether compounding is available or not.
Document everything. Keep substantiation files for every claim. If you can’t prove it, don’t say it.
The enforcement environment
This isn’t theoretical. The FTC and FDA are actively targeting GLP-1 telehealth marketing.
Warning letters typically give 15 days to respond. They require documented changes to marketing practices. Ignoring them escalates to civil penalties.
Civil penalties can reach $50,120 per violation. Repeated violations multiply.
The telehealth companies that survive this enforcement wave will be the ones that marketed compliantly from the start. The ones that overreached will spend years cleaning up warning letters and rebuilding trust.
Build for compliance now. It’s cheaper than fixing it later.